Octagam 50 mg/ ml Norra - norra - Statens legemiddelverk

octagam 50 mg/ ml

octapharma (2) - immunglobulin, normalt (humant) - infusjonsvæske, oppløsning - 50 mg/ ml

Panzyga 100 mg/ ml Norra - norra - Statens legemiddelverk

panzyga 100 mg/ ml

octapharma ab - immunglobulin, normalt, humant - infusjonsvæske, oppløsning - 100 mg/ ml

Thymoglobuline 25 mg Norra - norra - Statens legemiddelverk

thymoglobuline 25 mg

sanofi b.v. - immunglobulin anti-human thymocytt (kanin) - pulver til infusjonsvæske, oppløsning - 25 mg

Cuvitru 200 mg/ ml Norra - norra - Statens legemiddelverk

cuvitru 200 mg/ ml

baxalta innovations gmbh - immunglobulin, normalt, humant - injeksjonsvæske, oppløsning - 200 mg/ ml

Hepatect 50 IE/ ml Norra - norra - Statens legemiddelverk

hepatect 50 ie/ ml

biotest pharma gmbh - immunglobulin mot hepatitt b, humant - infusjonsvæske, oppløsning - 50 ie/ ml

Rhesonativ 625 IE/ ml Norra - norra - Statens legemiddelverk

rhesonativ 625 ie/ ml

octapharma as - immunglobulin anti-d, humant - injeksjonsvæske, oppløsning - 625 ie/ ml

Umanbig 180 IE/ ml Norra - norra - Statens legemiddelverk

umanbig 180 ie/ ml

kedrion s.p.a. - immunglobulin mot hepatitt b, humant - injeksjonsvæske, oppløsning - 180 ie/ ml

Atgam 50 mg/ ml Norra - norra - Statens legemiddelverk

atgam 50 mg/ ml

pfizer as - immunglobulin anti-t-lymfocytt, animalsk, til human bruk - konsentrat til infusjonsvæske, oppløsning - 50 mg/ ml

Flebogamma DIF (previously Flebogammadif) Euroopa Liit - norra - EMA (European Medicines Agency)

flebogamma dif (previously flebogammadif)

instituto grifols s.a. - humant normalt immunglobulin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - immune sera og immunglobuliner, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Hizentra Euroopa Liit - norra - EMA (European Medicines Agency)

hizentra

csl behring gmbh - human normal immunoglobulin (scig) - immunologiske mangelsyndrom - immune sera og immunglobuliner, - replacement therapy in adults, children and adolescents (0-18 years) in:- primary immunodeficiency syndromes with impaired antibody production (see section 4. - secondary immunodeficiencies (sid) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (psaf)* or serum igg level of.